Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.
Transpl Immunol
; 66: 101386, 2021 06.
Article
in En
| MEDLINE
| ID: mdl-33744409
ABSTRACT
Immune checkpoint inhibitors are increasingly used in the treatment of various solid tumors, including hepatocellular carcinoma (HCC). For liver transplant recipients, the safety of using immune checkpoint inhibitors before or after transplantation remains to be further explored. Former reports were mainly about posttransplant use of immune checkpoint inhibitors resulting in allograft rejection. Here we present one HCC patient who received toripalimab (an immune checkpoint inhibitor currently in phase 3 clinical trial for HCC) therapy before undergoing liver transplantation. He finally suffered fatal acute hepatic necrosis which is likely to be related to the acute immune rejection caused by the pretransplant use of toripalimab.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Liver Transplantation
/
Carcinoma, Hepatocellular
/
Antibodies, Monoclonal, Humanized
/
Graft Rejection
/
Liver Neoplasms
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Transpl Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
/
TRANSPLANTE
Year:
2021
Type:
Article
Affiliation country:
China